Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna van Rhenen

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Neuro-Oncology Advances|January 10, 2025
Post-intrathecal chemotherapy-related paraplegia syndrome in hematological cancer patients: A systematic reviewMatthijs Monnikhof, Gabriella Hamming, Sandra Crnko, et al.
JACC. Cardiooncology|August 16, 2021
Cancer Therapy-Related Cardiac Dysfunction of Nonanthracycline Chemotherapeutics: What Is the Evidence?Janine A M Kamphuis, Marijke Linschoten, Maarten J Cramer, et al.
The Lancet. Haematology|March 6, 2020
Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysisMarijke Linschoten, Janine A M Kamphuis, Anna van Rhenen, et al.
Stem Cells (Dayton, Ohio)|December 20, 2008
Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemiaBijan Moshaver, Anna van Rhenen, Angèle Kelder, et al.
Rheumatology (Oxford, England)|March 12, 2021
Severe thrombotic microangiopathy after autologous stem cell transplantation in systemic sclerosis: a case reportMaryam O Sharif, Helen L Leavis, Pieter van Paassen, et al.
Bone Marrow Transplantation|April 3, 2023
Graft engineering: how long can you wait, how low can you go, and pandemic readinessKlaartje Nijssen, Kasper Westinga, Anniek Stuut, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survivalAnna van Rhenen, Nicole Feller, Angèle Kelder, et al.
Blood|July 5, 2007
The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cellsAnna van Rhenen, Guus A M S van Dongen, Angèle Kelder, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 17, 2025
Clinicians' experiences, perspectives, barriers, and facilitators of integrating palliative care into hematological malignancy care: a qualitative interview studyBeaudine M van den Berg, Carly S Heipon, Corine Korf, et al.
European Heart Journal Open|September 10, 2025
Morning administration of anthracyclines is associated with a lower risk of cancer therapy-related cardiac dysfunctionMarkella I Printezi, Arco J Teske, Nicolaas P A Zuithoff, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Neuro-Oncology Advances|January 10, 2025
Post-intrathecal chemotherapy-related paraplegia syndrome in hematological cancer patients: A systematic reviewMatthijs Monnikhof, Gabriella Hamming, Sandra Crnko, et al.
JACC. Cardiooncology|August 16, 2021
Cancer Therapy-Related Cardiac Dysfunction of Nonanthracycline Chemotherapeutics: What Is the Evidence?Janine A M Kamphuis, Marijke Linschoten, Maarten J Cramer, et al.
The Lancet. Haematology|March 6, 2020
Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysisMarijke Linschoten, Janine A M Kamphuis, Anna van Rhenen, et al.
Stem Cells (Dayton, Ohio)|December 20, 2008
Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemiaBijan Moshaver, Anna van Rhenen, Angèle Kelder, et al.
Rheumatology (Oxford, England)|March 12, 2021
Severe thrombotic microangiopathy after autologous stem cell transplantation in systemic sclerosis: a case reportMaryam O Sharif, Helen L Leavis, Pieter van Paassen, et al.
Bone Marrow Transplantation|April 3, 2023
Graft engineering: how long can you wait, how low can you go, and pandemic readinessKlaartje Nijssen, Kasper Westinga, Anniek Stuut, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survivalAnna van Rhenen, Nicole Feller, Angèle Kelder, et al.
Blood|July 5, 2007
The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cellsAnna van Rhenen, Guus A M S van Dongen, Angèle Kelder, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 17, 2025
Clinicians' experiences, perspectives, barriers, and facilitators of integrating palliative care into hematological malignancy care: a qualitative interview studyBeaudine M van den Berg, Carly S Heipon, Corine Korf, et al.
European Heart Journal Open|September 10, 2025
Morning administration of anthracyclines is associated with a lower risk of cancer therapy-related cardiac dysfunctionMarkella I Printezi, Arco J Teske, Nicolaas P A Zuithoff, et al.
Pageof 4